{"filings":[{"id":1473637,"accession_number":"0001832511-26-000029","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-07-06T21:02:51+00:00","items":["1.01","9.01"],"status":"ready","headline":"P3 Health extends note maturity to Sep 2028, switches to 14% PIK interest","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Second Amendment to Repurchase Promissory Note with IHC Health Services, Inc. executed June 30, 2026.","Maturity date extended from original to September 30, 2028.","Interest accrues as PIK at 14% per annum from June 30, 2026 onward.","Note originally dated June 28, 2019; previously amended November 19, 2020.","All other terms of the Note remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":954212,"accession_number":"0001832511-26-000027","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-06-09T21:54:42+00:00","items":["5.07","9.01"],"status":"ready","headline":"P3 Health Partners shareholders approve all four proposals at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected three Class II directors: Bacchus (4,067,100 for), Thierer (4,081,573), Leisure (3,980,136).","Ratified BDO USA as independent auditor for FY2026 (4,484,963 for, 39,585 against).","Advisory say-on-pay approved (4,084,583 for, 9,786 against).","Approved issuance of up to 3,341,130 shares upon exercise of warrants held by VBC Growth SPV 5, LLC (4,064,690 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":667561,"accession_number":"0001832511-26-000026","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-05-26T20:06:05+00:00","items":["3.01","9.01"],"status":"ready","headline":"P3 Health Partners regains Nasdaq compliance on Listing Rule 5550(b)(2)","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on May 20, 2026 confirming compliance with continued listing standards.","Compliance determination based on Company's Form 8-K filed May 15, 2026.","Previously disclosed non-compliance with Nasdaq Listing Rule 5550(b) on November 28, 2025.","Company now satisfies the $35 million market value of listed securities requirement under Rule 5550(b)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":472596,"accession_number":"0001832511-26-000024","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-05-15T20:58:03+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"P3 Health Partners exchanges $252M debt for preferred stock, issues $30M Series D units to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged ~$252.5M of promissory notes (principal, accrued interest, fees) for non-convertible, non-voting preferred stock.","Issued $30M of Series D 19.5% Cumulative Preferred Stock + warrants to CPF as first tranche of up to $70M.","Believes it has regained compliance with Nasdaq minimum $2.5M stockholders' equity requirement; extension through May 20, 2026.","Pro forma total stockholders' equity improved from ($143.5M) to $82.1M after Debt Exchange and Series D issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442720,"accession_number":"0001832511-26-000021","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-05-14T20:10:41+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners reports Q1 net income $3M, raises FY 2026 adjusted EBITDA guidance to $20-60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $386M (+4% YoY); net income $3M vs net loss $44.2M prior year.","Adjusted EBITDA $25.8M ($81 PMPM); cites contract restructuring and operational redesign.","At-risk membership ~106,000, down 10% YoY due to intentional network rationalization.","Full-year 2026 adjusted EBITDA guidance raised to $20-$60M (midpoint $40M).","Medical margin $73.7M; excluding prior-year development and settlements $56.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":386390000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95997,"accession_number":"0001832511-26-000018","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"P3 converts ~$252.5M debt to preferred stock, raises $10M to regain Nasdaq equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Exchanged ~$252.5M promissory notes for Series A/B/C preferred stock (13.5%-19.5% dividends) to boost stockholders' equity.","Secured up to $70M in Series D preferred plus warrants from largest holder CPF; initial $10M tranche closed.","Standstill extended to Jan 1, 2027; CPF may designate independent director if ownership exceeds 40%.","Special committee negotiated transactions; intended to satisfy Nasdaq minimum equity requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109487,"accession_number":"0001832511-26-000010","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners reports Q4 net loss $165.7M, provides 2026 EBITDA guidance midpoint $10M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $384.8M, net loss $165.7M, adjusted EBITDA loss $76.1M.","Full-year 2025 revenue $1.46B, net loss $323.1M, adjusted EBITDA loss $161.3M.","At-risk membership declined ~9% to ~115,000 in Q4 due to network realignment.","2026 guidance: adjusted EBITDA range -$20M to +$40M, midpoint $10M, ~$170M YoY improvement.","Normalized full-year adjusted EBITDA loss improved to $149.1M from $193.0M in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109486,"accession_number":"0001832511-26-000006","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"P3 Health Partners enters Nebraska Medicare Advantage agreement with large nonprofit health insurer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["P3 will provide clinical, operational, and data-driven support to primary care providers in client’s Nebraska Medicare Advantage network.","Management services fees for performance years 2026 and 2027; global risk arrangement for 2028 and beyond.","Master Services Agreement initial term through Dec 31, 2030, with automatic one-year renewal unless 180-day notice given.","Client may terminate SOW upon 90-day notice if P3 fails to meet agreed performance metrics for 2026 or if key persons depart.","If client opts not to pursue CMS Medicare Advantage bid for 2027-2028, SOW terminates with break-up fee covering actual costs plus direct termination costs, capped at an agreed amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109485,"accession_number":"0001832511-26-000005","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"P3 Health extends $19M draw period on $40M promissory note tranche to June 30, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment to existing $40M third tranche allows draws of remaining $19M through June 30, 2026.","Originally dated May 29, 2025; all other Note terms unchanged.","No new borrowing; simply extends draw availability on previously committed facility.","Counterparty is VBC Growth SPV 5, LLC (affiliate of Chicago Pacific Founders)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126004,"accession_number":"0001832511-25-000028","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"P3 Health Partners receives Nasdaq deficiency notice for failing to meet minimum stockholders' equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Nov 21, 2025, Nasdaq notified P3 Health Partners that it lacks the $2.5M minimum stockholders' equity required by Listing Rule 5550(b)(1).","Company also does not meet the alternatives of market value of listed securities or net income from continuing operations.","Letter has no immediate delisting effect; company has 45 calendar days to submit a plan to regain compliance.","If plan accepted, Nasdaq may grant an extension of up to 180 calendar days from Nov 21, 2025 to evidence compliance.","Company intends to submit a compliance plan and is pursuing steps to restore compliance, though no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126003,"accession_number":"0001832511-25-000024","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners Q3 revenue $345.3M (-5% YoY); adjusted EBITDA loss $45.9M; narrows guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["At-risk membership ~116k (-10% YoY) due to intentional network/payer rationalization.","Medical margin $4.4M ($13 PMPM) impacted by unfavorable mid-year settlement adjustments.","Adjusted EBITDA loss $45.9M ($132 PMPM); YTD normalized loss $70.1M ($67 PMPM).","FY 2025 guidance: revenue $1.4B-$1.45B; adjusted EBITDA loss $(110)M-$(95)M.","Identified $120M-$170M EBITDA expansion opportunity; targeting profitability in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-22.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1074266000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126002,"accession_number":"0001832511-25-000023","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"P3 Health Partners forms MSO JV with Commonwealth Primary Care ACO (80/20 split)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["P3 subsidiary P3 ACO holds 80% interest; CPC ACO holds 20% in new MSO Delaware LLC.","MSO will manage ACO activities: shared services, financial mgmt, compliance, data analytics.","Management fee equals liabilities assumed plus fair-market-value margin; shared savings from 2026.","P3 ACO may redeem CPC ACO's interest after three years; CPC can force redemption if P3 fails to act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142736,"accession_number":"0001832511-25-000015","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"P3 Health Partners extends term loan interest-only period to Sep 2026; maturity to Dec 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Interest-only period extended to September 30, 2026; maturity extended to December 31, 2027.","Interest rate remains 12% through Dec 31, 2025, then increases to 15% after.","Principal payments reset to fixed $5 million per payment date following interest-only period.","Amendment replaces single PIK period with two: first (thru Dec 2024) 8% cash+4% PIK; second (Jan 2026-Dec 2027) 12% cash+3% PIK.","Lender representatives receive board observation rights at borrower's holding company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142735,"accession_number":"0001832511-25-000010","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners Q2 revenue down 6% YoY; adj. EBITDA loss $17.1M; FY guidance lowered","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Average at-risk membership ~115,000, down 9% YoY due to network/payer rationalization.","Revenue $355.8M (-6% YoY); medical margin $30.6M ($89 PMPM). Excl. prior-period adj., medical margin $39.3M.","Adjusted EBITDA loss $17.1M ($50 PMPM); excl. prior-period adj., loss was $8.5M ($25 PMPM).","FY 2025 guidance: revenue $1.35B-$1.5B, medical margin $124M-$154M, adj. EBITDA loss $69M-$39M.","Identified $120M-$170M in additional EBITDA opportunities; three of four markets EBITDA positive/breakeven."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":729013000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142734,"accession_number":"0001628280-25-034559","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"P3 Health Partners appoints CEO Aric Coffman to board after Dr. Abdou resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sherif Abdou resigned from the Board effective July 2, 2025; transition services agreement expired April 30, 2025.","Dr. Aric Coffman, CEO of P3 Health Partners, appointed as Class I director effective July 8, 2025, term expiring 2028.","Dr. Coffman is not independent due to his CEO role; he will not serve on any Board committees.","Dr. Coffman will not receive additional compensation for board service.","Board unanimously approved appointment on recommendation of Nominating Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160814,"accession_number":"0001628280-25-030297","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"P3 Health Partners shareholders elect three Class I directors, approve auditor and warrant issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sherif Abdou, Greg Kazarian, Greg Wasson elected as Class I directors with >209M votes each.","BDO USA ratified as independent auditor for FY2025; 232M votes for, 690K against.","Advisory vote on executive compensation passed with 211.8M votes for.","Issuance of up to 1,428,129 shares upon warrant exercise by VBC Growth SPV 4, LLC approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160813,"accession_number":"0001628280-25-029146","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"P3 Health Partners secures up to $70M unsecured promissory note at 19.5% interest, issues warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["First tranche $15M drawn; second $15M due by June 22, 2025; third $40M mutually agreed by Dec 31, 2025.","Note matures Aug 13, 2028; interest 19.5% p.a. (11.5% PIK option); default rate adds 4%.","Warrants for 1,430,281 shares at $7.39/share exercisable after Nasdaq stockholder approval; terminate May 29, 2032.","Back-end fee ranges from 2.25% to 9% depending on repayment date; proceeds for working capital.","Approved by independent committee; VBC 5 is affiliate of principal stockholder (Chicago Pacific Founders)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160812,"accession_number":"0001628280-25-025928","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners Q1 revenue down 4%, medical margin hit by $23M prior-year claims adjustment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $373.2M, down 4% YoY; average at-risk membership 115,900 (-8%).","Medical margin $17.2M vs $36.6M prior year; includes negative $23M net impact from prior-year claims from one payer.","Adjusted EBITDA loss $22.2M vs $19.8M loss prior year; includes negative $9M prior claims and retroactive adjustments.","FY2025 guidance affirmed: revenue $1.35B-$1.5B, medical margin $174M-$210M, Adj. EBITDA -$35M to $5M.","CEO says turnaround ahead of schedule; 3 of 4 markets achieved breakeven or better in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":373225000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160811,"accession_number":"0001628280-25-018083","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"P3 Health Partners effects 1-for-50 reverse stock split effective April 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split applied to Class A and Class V common stock at a 1-for-50 ratio.","No fractional shares issued; stockholders receive cash in lieu based on closing price.","Proportional adjustments made to equity awards, warrants, and incentive plans.","Class A common stock began trading split-adjusted on April 14, 2025 under symbol 'PIII'.","New CUSIP for Class A common stock is 744413 204; warrants CUSIP unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160810,"accession_number":"0001628280-25-016833","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"P3 Health Partners announces 1-for-50 reverse stock split effective April 11, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at March 31 special meeting; board set ratio at 1-for-50.","Reverse split effective 5:00 p.m. ET on April 11; split-adjusted trading begins April 14 under PIII.","No fractional shares issued; cash payment for fractional shares based on closing price on effective date.","Warrants continue under PIIIW with same CUSIP; adjustments to equity awards and warrants.","New CUSIP for Class A common stock: 744413 204."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160809,"accession_number":"0001628280-25-016337","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"P3 Health Partners shareholders approve reverse stock split at 1:10-1:60 ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting held March 31, 2025; both proposals approved by stockholders.","Proposal 1 (reverse stock split): 227,773,176 FOR, 9,377,137 AGAINST, 10,925 abstain.","Proposal 2 (adjournment): 227,648,046 FOR, 9,484,329 AGAINST, 28,863 abstain.","Board to set final ratio between 1:10 and 1:60 and announce timing.","No other matters voted on at the Special Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179010,"accession_number":"0001628280-25-015165","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners FY2024 net loss widens to $310.4M; revenue up 18% to $1.50B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year net loss $310.4M vs $186.4M prior; adjusted EBITDA loss $167.2M vs $85.5M.","Q4 net loss $129.1M vs $69.1M; medical margin fell 37% to $85.5M for the year.","At-risk membership grew 14% to 123,800; total revenue $1.50B (+18% YoY).","FY2025 guidance: revenue $1.35B-$1.50B, adjusted EBITDA loss ($35M)-$5M, at-risk members 109k-119k."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179009,"accession_number":"0001628280-25-005930","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"P3 Health Partners secures $30M loan at 19.5% interest, issues warrants for 71.4M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$30M unsecured promissory note from VBC Growth SPV 4 (affiliate of principal stockholder), drawn in two $15M tranches.","Interest at 19.5% per annum; company may pay 8% cash + 11.5% PIK or all in-kind if subordination restricts cash.","Warrants to buy 71,406,480 shares at $0.2068 per share, exercisable only after stockholder approval sought at 2025 annual meeting.","Maturity August 13, 2028; up-front fee 1.5% of $30M; back-end fee up to 9.0% depending on repayment timing.","Proceeds fund working capital; note is subordinated to existing CRG term loan facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179008,"accession_number":"0001628280-25-005308","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"P3 Health Partners provides preliminary 2025 guidance; proposes $30M note from largest shareholder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary 2025 revenue guidance of $1.35B-$1.5B; Adjusted EBITDA of $(35)M to $5M.","At-risk members guidance of 108k-118k for FY2025.","Proposed $30M unsecured promissory note and warrants from largest shareholder, terms similar to Dec 2024 financing.","CEO states $130M+ EBITDA growth initiatives on track; targeting profitability in 2025.","Full 2025 guidance to be issued with Q4 2024 earnings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195694,"accession_number":"0001628280-24-051677","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"P3 Health Partners secures $25M financing from affiliate with 71.4M warrants at $0.2137/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["P3 LLC subsidiary entered a $25M unsecured promissory note with VBC 3 at 19.5% interest, maturing June 30, 2028.","Warrants to purchase 71,406,480 shares of common stock at $0.2137 per share issued to VBC 3.","Refinanced existing 2022 loan with VBC 1 at 0.5% lower interest; back-end fee waived.","Proceeds to fund working capital; CPF standstill extended through January 1, 2026.","Note subordinated to existing term loan; interest may be paid in-kind under subordination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195693,"accession_number":"0001628280-24-047123","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Q3 revenue $362.1M (+26% YoY) but net loss widens to $102.9M; withdraws FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $362.1M, up 26% YoY; capitated revenue $357.7M (+25%).","Net loss $102.9M vs $37.3M loss in Q3 2023; Adjusted EBITDA loss $71.0M.","Medical margin nearly zero at $0.5M vs $36.2M prior year; gross profit loss $39.8M.","Withdraws FY2024 guidance due to lower risk adjustment, prior negative developments, elevated medical costs.","CEO highlights $130M+ potential improvement opportunities; demand for platform remains strong."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":1129769000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211960,"accession_number":"0001628280-24-038802","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"P3 Health Partners names Leif Pedersen as CFO effective Oct 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leif Pedersen appointed CFO effective October 1, 2024; succeeds Atul Kavthekar, who resigned.","Kavthekar's resignation not due to any disagreement; he will serve as advisor post-transition.","Pedersen most recently VP Finance at UnitedHealth Group-Optum Health; previously at DaVita.","Compensation: $440K base salary, 50% target bonus, equity grants of 1.5M shares (options + RSUs).","Severance: 6 months base salary if terminated without cause after 6 months, subject to mitigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211959,"accession_number":"0001628280-24-035600","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners Q2 revenue up 15% to $379.2M; net loss widens to $28.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $379.2M (+15% YoY); capitated revenue $374.3M (+15% YoY).","Gross profit $14.0M (down from $26.8M); medical margin $41.1M (down from $50.5M).","Net loss $28.8M (vs $27.6M); Adjusted EBITDA loss $8.8M (vs +$0.2M).","FY2024 guidance: revenue $1.45-$1.55B; medical margin $230-$250M; Adjusted EBITDA $20-$40M.","CEO cites top-line growth and balance sheet improvement from capital raise."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":767645000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230774,"accession_number":"0001628280-24-027325","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"P3 Health Partners annual meeting elects three directors, ratifies auditor, approves executive compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected three Class III directors: Jeffrey G. Park, Thomas E. Price, Mary Tolan, with votes ranging from 187M to 189M for.","Ratified BDO USA as independent auditor for FY2024 with 200.6M votes for, 110K against.","Advisory approval of named executive officer compensation with 191.5M for, 294K against.","Approved 'ONE YEAR' frequency for future advisory votes on executive compensation (166.3M for one year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230773,"accession_number":"0001104659-24-065141","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"P3 Health Partners raises $42.2M in private placement of 67.4M units with warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued ~67.4M units at ~$0.6270 each; each unit = 1 share Class A + 1 warrant (exercise $0.5020, 7-year term).","Gross proceeds ~$42.2M; pre-funded warrants used in lieu of shares for some institutional investors.","Chicago Pacific Partners purchased ~31.9M units ($20M); standstill restriction extended to July 31, 2025.","CPF gets board designation rights for one independent director if it holds 40% of outstanding common stock.","Registration rights agreement filed; company to register resale of shares and warrant shares within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230772,"accession_number":"0001104659-24-064559","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"P3 Health Partners raises ~$42.2M via private placement of ~67.4M units at $0.627/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$42.2M; each unit priced at ~$0.6270, closing expected May 24, 2024.","Each unit comprises one Class A share and a warrant (exercise $0.5020, 7-year term).","Institutional investors may opt for pre-funded warrants at $0.0001 per share.","CPF purchased ~31.9M units for ~$20M; standstill extended to July 31, 2025.","CPF gains board designation rights if it holds 40% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230771,"accession_number":"0001628280-24-024334","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"P3 Health Partners receives Nasdaq bid price deficiency notice; 180-day cure period ends Nov 11, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on May 15, 2024 for common stock (PIII) bid price below $1.00 for 31 straight business days.","Must close at $1.00 or higher for at least 10 consecutive business days by November 11, 2024 to regain compliance.","If not compliant by Nov 11, may qualify for an additional 180-day period if other listing standards are met.","Stock remains listed for now; company will evaluate available options to cure the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230770,"accession_number":"0001628280-24-022303","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"P3 Health Partners appoints Dr. Aric Coffman as CEO, replacing Dr. Sherif Abdou effective May 8, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Coffman receives $750K base salary, 75% target bonus, and equity awards covering 16.5M shares (12.1M options, 4.4M RSUs).","Outgoing CEO Dr. Abdou becomes Vice Chair of Board and Senior Advisor under consulting agreement for $400K fee through April 2025.","Board adopts 2024 Employment Inducement Incentive Award Plan reserving 16.5M shares for inducement grants.","Dr. Coffman previously CEO of Honest Medical Group; held leadership roles at DaVita Medical Group and Optum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230769,"accession_number":"0001628280-24-021663","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners Q1 revenue up 29% to $388.5M; appoints Dr. Aric Coffman as CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $388.5M (+29% YoY); capitated revenue $384.1M; net loss improved to $49.6M from $52.4M.","Medical margin $36.6M vs $39.2M prior year; gross profit fell to $6.4M from $16.5M.","Reaffirms FY2024 guidance: revenue $1.45-1.55B, medical margin $230-250M, adjusted EBITDA $20-40M.","Dr. Aric Coffman appointed CEO; company anticipates reaching adjusted EBITDA positive in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":388488000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249154,"accession_number":"0001628280-24-013613","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","2.02","2.03","8.01","9.01"],"status":"ready","headline":"P3 Health reports FY23 revenue $1.27B (+21% YoY); affirms 2024 Adj. EBITDA guidance $20M-$40M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1.27B for FY2023 (+21% YoY); net loss $186.4M vs $1.56B prior year.","Medical margin $135.1M (+118% YoY); Adjusted EBITDA loss $85.5M (improved from $127.9M).","Affirms 2024 guidance: at-risk members 125k-135k, revenue $1.45B-$1.55B, Adj. EBITDA $20M-$40M.","P3 LLC entered $25M unsecured promissory note (17.5% interest) from VBC Growth SPV 2 for growth pipeline.","Note subordinated to existing term loan; related-party transaction approved by independent committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249153,"accession_number":"0001628280-24-010546","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"P3 Health Partners adopts bylaw amendments on universal proxy and stockholder nominations","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Amended and Restated Bylaws effective March 8, 2024.","Amendments require compliance with SEC universal proxy rules (Rule 14a-19) for soliciting proxies for non-Board nominees.","Enhanced disclosure requirements for stockholder director nominations and other business proposals.","Proxy card other than white is required for stockholder proxy solicitations; white reserved for Board.","Obsolete provisions removed; technical and clarifying changes made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249152,"accession_number":"0001628280-24-000993","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"P3 Health reaffirms 2023 guidance; 2024 revenue $1.45B-$1.55B, positive EBITDA $20M-$40M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 reaffirmed: revenue $1.2B-$1.25B, medical margin $155M-$175M, Adj. EBITDA loss $30M-$50M.","FY2024 guidance: revenue $1.45B-$1.55B, medical margin $230M-$250M, Adj. EBITDA positive $20M-$40M.","Medicare Advantage members expected 125k-135k in 2024, up from 115k-120k in 2023.","Medical margin PMPM guided $165-$175 in 2024, up from $120-$130 in 2023.","Management expects meaningful profitability in 2024, citing robust pipeline and managed cost trend."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":1266375000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266658,"accession_number":"0001104659-23-117421","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"P3 Health Partners amends registration rights to exclude new S-3 and ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment and waiver to Registration Rights Agreement entered on Nov 8, 2023 with majority stockholders.","Excludes the Nov 9, 2023 S-3 shelf registration from 'Primary Offering Registration Statement' definition.","Waives underwritten offering and piggyback rights under Section 1.9 for the S-3 and ATM program.","Enables company to proceed with new shelf registration and at-the-market offering without triggering stockholder rights.","Effective date of amendment is concurrent with filing of the Registration Statement and ATM program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266657,"accession_number":"0001104659-23-116284","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"P3 Health Partners files historical Foresight Acquisition Corp. audited financials for 2020-2021 period","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audited financials cover Foresight Acquisition Corp. (predecessor to P3) as of Dec 2, 2021 and Dec 31, 2020, and periods from inception (Aug 20, 2020) through Dec 2, 2021.","Foresight had net loss of $24.8M for Jan 1-Dec 2, 2021; cash and cash equivalents of $100,935 as of Dec 2, 2021.","Going concern note: Foresight's cash and working capital insufficient to complete planned activities absent business combination (completed Dec 3, 2021).","Filing made solely to incorporate financials by reference into P3's registration statements; no new business or operational update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266656,"accession_number":"0001628280-23-037818","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"P3 Health Partners Q3 revenue $288.4M (+16% YoY); net loss narrows; guides for positive 2024 Adj EBITDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $288.4M, up 16% YoY; net loss $37.3M vs. $65.3M loss prior year.","Adjusted EBITDA loss $22.3M, improved from $40.3M loss YoY; medical margin $36.2M, +306%.","YTD total revenue $919.5M (+16%); net loss $117.3M vs. $1,029.2M loss (incl. $851M goodwill impairment).","Reaffirms FY 2023 guidance: revenue $1.2B-$1.25B, Adj EBITDA loss $(50)-$(30)M; MA members 115k-120k.","Preliminary FY 2024 Adj EBITDA guidance of +$20M to +$40M, signaling expected profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":919514000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283904,"accession_number":"0001628280-23-027768","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Q2 capitated revenue $325.6M (+22% YoY); Adj EBITDA turns positive at $0.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 capitated revenue $325.6M (+22% YoY); medical margin $50.5M (+132%).","Adjusted EBITDA turned positive at $0.2M vs -$28.7M loss a year ago.","Net loss $27.6M vs $903.1M (prior-year loss included $851.5M goodwill impairment).","Full-year 2023 guidance: revenue $1.20-1.25B, Adj EBITDA loss $(50)-(30)M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":631163000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283903,"accession_number":"0001628280-23-025717","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"P3 Health Partners shareholders elect three Class II directors and ratify BDO as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Dr. Amir Bacchus (203.3M for, 39.8M withheld), Mark Thierer (203.5M for, 39.6M withheld), Lawrence B. Leisure (195.9M for, 47.1M withheld).","Ratified BDO USA, LLP as independent auditor for FY 2023 (247.5M for, 0.2M against).","Both proposals passed; brokers had 4.6M non-votes on director election and none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303488,"accession_number":"0001628280-23-017225","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Q1 capitated revenue up 11%; net loss improves 14%; medical margin surges 58%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Capitated revenue $298.7M (+11% YoY); net loss $52.4M, improved from $60.8M in Q1 2022.","Medical margin $39.2M (13.1% of capitated revenue), up 58% YoY; network contribution $16.5M (+114%).","Adjusted EBITDA loss $19.1M; full-year guidance raised to loss $35-55M from prior expectations.","FY 2023 guidance: revenue $1.2-1.25B, medical margin $155-175M, members 115k-120k."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":302077000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303487,"accession_number":"0001104659-23-049296","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"P3 Health Partners sets 2023 annual meeting for July 24; proxy deadline May 5","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for July 24, 2023, held virtually via remote communication.","Stockholder proposals and director nominations must be received by May 5, 2023.","Notice must comply with company Bylaws and Rule 14a-19 for universal proxy rules.","No financial or operational changes announced; routine procedural event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303486,"accession_number":"0001104659-23-042915","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-04-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"P3 Health Partners closes $89.5M private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$89.5M gross from sale of 69.2M shares and warrants for 59.9M shares plus pre-funded warrants.","Chicago Pacific Partners invested ~$71M, acquiring 52.8M shares, 10.8M pre-funded warrants, and 47.6M warrants.","Warrants have $1.13 exercise price, 5-year term; pre-funded warrants exercise at $0.0001 per share.","Company to file resale registration statement within 30 days; CPF gets board designee right if ownership ≥40%.","CPF agreed to standstill until June 30, 2024, limiting ownership to 49.99% of common and Class V common."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323128,"accession_number":"0001104659-23-039658","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"P3 Health Partners raises ~$89.5M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued ~69.2M shares, ~59.9M warrants, ~10.8M pre-funded warrants at ~$1.12/unit for institutions, ~$1.19 for employees/consultants.","CPF affiliates purchase ~$71M of the offering, including ~52.8M shares, ~10.8M pre-funded warrants, ~47.6M warrants.","Closing expected April 6, 2023; registration statement to be filed within 30 days post-closing.","CPF gets board designation and information rights if ownership >=40%, and standstill until June 30, 2024 limiting ownership to 49.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323127,"accession_number":"0001104659-23-039608","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"P3 Health Partners Q4 2022 net loss $532.3M on $463.5M goodwill impairment; revenue up 40%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 capitated revenue $254.0M (+40% YoY); net loss $532.3M vs $118.2M loss, primarily due to $463.5M goodwill impairment.","Adjusted EBITDA loss $40.1M vs $35.6M; Adjusted EBITDA PMPM loss improved to $133 from $177 in Q4 2021.","Full-year 2022 network contribution improved 65% vs 2021; company affirms 2023 guidance, expects Adjusted EBITDA positive in early 2024.","Introduced year-end medical margin guidance as new non-GAAP metric."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":302077000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323126,"accession_number":"0001104659-23-032430","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"P3 Health Partners reaffirms FY2022 guidance and provides FY2023 outlook; 10-K filing delayed to March 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirmed FY2022 revenue $1.025B-$1.075B (61%-69% YoY growth) and >100k at-risk MA members.","FY2022 adjusted EBITDA loss reaffirmed at $118M-$128M; FY2023 adjusted EBITDA loss guided at $40M-$60M.","Preliminary 2023 revenue guidance $1.20B-$1.25B; at-risk MA membership 115k-120k.","Expects positive adjusted EBITDA in 2024; 10-K filing delay due to audit timing, not operational issues.","Earnings call scheduled for March 30, 2023 after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323125,"accession_number":"0001104659-23-006531","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"P3 Health Partners CAO Erin Darakjian resigns; CFO to serve as principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erin Darakjian resigned as Chief Accounting Officer effective January 27, 2023.","CFO Atul Kavthekar designated principal accounting officer effective the same date.","Resignation was a personal decision, not due to any disagreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323124,"accession_number":"0001104659-23-003071","cik":1832511,"company_name":"P3 Health Partners Inc.","ticker":"PIII","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"P3 Health reaffirms 2022 guidance, sees 2023 revenue $1.2B-$1.25B, narrower EBITDA loss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirmed FY2022 revenue $1.025B-$1.075B (61-69% YoY growth); at-risk MA membership >100k.","FY2023 guidance: revenue $1.20B-$1.25B, membership 115k-120k, Adj. EBITDA loss $40M-$60M.","Company anticipates achieving positive Adj. EBITDA in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":115412809.53117783,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-11T23:59:59+00:00|323124"}